Robert Michael Tuttle

Robert Michael Tuttle's AcademicInfluence.com Rankings

Philosophy

#7632

World Rank

#10873

Historical Rank

Logic

#4677

World Rank

#5998

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Robert Michael Tuttle's Degrees

Doctorate Medicine Harvard University

Why Is Robert Michael Tuttle Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Robert Michael Tuttle's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. (2009) (7672)
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. (2009) (7330)
Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. (2006) (2111)
Integrated Genomic Characterization of Papillary Thyroid Carcinoma (2014) (2007)
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. (2013) (784)
Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. (2010) (768)
American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. (2012) (711)
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. (2013) (611)
The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. (2012) (607)
Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. (2006) (525)
Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. (2009) (521)
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. (2009) (495)
Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. (2015) (412)
Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? (2017) (408)
Follicular variant of papillary thyroid carcinoma (2006) (331)
Consensus Statement #1: Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and The Endocrine Society. (2005) (328)
Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. (2004) (305)
Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance (2017) (284)
Rising incidence of second cancers in patients with low‐risk (T1N0) thyroid cancer who receive radioactive iodine therapy (2011) (280)
Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasia by fine-needle aspiration. (1998) (278)
Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. (2012) (275)
The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. (2000) (252)
Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis (2006) (251)
A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma. (2016) (235)
American Thyroid Association statement on outpatient thyroidectomy. (2013) (219)
Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy (2012) (216)
Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. (2006) (208)
American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. (2011) (201)
Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual (2018) (190)
Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. (2001) (186)
Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance? (2016) (182)
The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. (2012) (179)
Thyroid carcinoma, version 2.2014. (2014) (176)
Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. (2001) (175)
Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine. (2016) (168)
Genome-wide appraisal of thyroid cancer progression. (2002) (168)
Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? (2002) (167)
Changing Trends in the Incidence of Thyroid Cancer in the United States. (2016) (165)
Diagnostic Accuracy of 18F-FDG PET in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin Levels (2007) (162)
An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer. (2016) (161)
A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. (2002) (154)
Update on differentiated thyroid cancer staging. (2014) (150)
Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems. (2013) (134)
Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern). (2009) (128)
Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant. (2015) (125)
Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience. (2009) (123)
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. (2018) (120)
Salivary Gland Side Effects Commonly Develop Several Weeks After Initial Radioactive Iodine Ablation (2009) (120)
Suspicious cervical lymph nodes detected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients. (2012) (119)
The impact of microscopic extrathyroid extension on outcome in patients with clinical T1 and T2 well-differentiated thyroid cancer. (2011) (118)
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. (2001) (112)
Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease. (1995) (111)
Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. (2010) (111)
Recombinant Human TSH–Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal (2008) (111)
Follow up approaches in thyroid cancer: a risk adapted paradigm. (2008) (110)
Skeletal-related events due to bone metastases from differentiated thyroid cancer. (2012) (109)
In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. (2011) (106)
Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It? (2015) (105)
Thyroid – Differentiated and Anaplastic Carcinoma (2017) (105)
The Japanese Tsunami and Resulting Nuclear Emergency at the Fukushima Daiichi Power Facility: Technical, Radiologic, and Response Perspectives (2011) (105)
Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland (2006) (104)
Outcomes in patients with poorly differentiated thyroid carcinoma. (2014) (103)
Follicular variant of papillary thyroid carcinoma: Genome‐wide appraisal of a controversial entity (2004) (102)
European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. (2019) (101)
Management of recurrent/persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance. (2015) (101)
Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression. (2011) (99)
Outcome of Large Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. (2017) (99)
The Effect of Posttherapy 131I SPECT/CT on Risk Classification and Management of Patients with Differentiated Thyroid Cancer (2010) (94)
Management of advanced medullary thyroid cancer. (2016) (92)
The impact of nodal status on outcome in older patients with papillary thyroid cancer. (2014) (88)
Dissecting Anaplastic Thyroid Carcinoma (ATC): A Comprehensive Clinical, histologic, Immunophenotypic, and Molecular Study of 360 Cases. (2020) (85)
Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. (2010) (83)
Papillary thyroid cancer: monitoring and therapy. (2007) (83)
Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. (2004) (83)
Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer (2016) (82)
Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy? (2012) (79)
Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. (2012) (78)
Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer. (2005) (77)
Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up. (2019) (77)
Five-Year Survival Is Similar in Thyroid Cancer Patients with Distant Metastases Prepared for Radioactive Iodine Therapy with either Thyroid Hormone Withdrawal or Recombinant Human TSH (2011) (75)
Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates (2015) (75)
Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry–Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer (2017) (74)
Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. (2004) (74)
Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence (2017) (74)
The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. (2013) (73)
Anaplastic Thyroid Carcinoma: A 25-year Single-Institution Experience (2014) (72)
Clinical presentation and clinical outcomes in Chernobyl-related paediatric thyroid cancers: what do we know now? What can we expect in the future? (2011) (69)
Medical management of thyroid cancer: a risk adapted approach (2008) (68)
American Thyroid Association statement on the essential elements of interdisciplinary communication of perioperative information for patients undergoing thyroid cancer surgery. (2011) (68)
Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. (2015) (67)
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center. (2020) (67)
Autoimmune thyroid disease associated with environmental thyroidal irradiation. (2003) (66)
The Chernobyl accident and its consequences: update at the millennium. (2000) (65)
Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. (2010) (65)
Prophylactic Central Neck Dissection in Differentiated Thyroid Cancer: An Assessment of the Evidence (2013) (63)
Outcomes for patients with papillary thyroid cancer who do not undergo prophylactic central neck dissection (2016) (63)
Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. (2012) (63)
Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. (2015) (62)
Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma. (2013) (61)
Risk-adapted management of thyroid cancer. (2008) (60)
Impact of pregnancy on serum thyroglobulin and detection of recurrent disease shortly after delivery in thyroid cancer survivors. (2007) (60)
Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell‐derived thyroid carcinoma (2017) (59)
ACTIVE SURVEILLANCE FOR PAPILLARY THYROID MICROCARCINOMA: NEW CHALLENGES AND OPPORTUNITIES FOR THE HEALTH CARE SYSTEM. (2016) (58)
A JOINT STATEMENT FROM THE AMERICAN THYROID ASSOCIATION. (2021) (58)
Prognostic implications of papillary thyroid carcinoma with tall-cell features. (2014) (58)
Operative management of locally advanced, differentiated thyroid cancer. (2016) (57)
Controversial Issues in Thyroid Cancer Management (2018) (57)
External‐beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society (2016) (57)
Prognostic impact of extent of vascular invasion in low-grade encapsulated follicular cell-derived thyroid carcinomas: a clinicopathologic study of 276 cases. (2015) (55)
The impact of initial surgical management on outcome in young patients with differentiated thyroid cancer. (1998) (54)
The evolving diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). (2018) (53)
A clinical framework to facilitate selection of patients with differentiated thyroid cancer for active surveillance or less aggressive initial surgical management (2018) (52)
Thyroid Lobectomy Is Associated with Excellent Clinical Outcomes in Properly Selected Differentiated Thyroid Cancer Patients with Primary Tumors Greater Than 1 cm (2013) (51)
Incidence and Significance of Delphian Node Metastasis in Papillary Thyroid Cancer (2011) (50)
External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non‐anaplastic non‐medullary thyroid cancer (2014) (49)
Pediatric Differentiated Thyroid Carcinoma of Follicular Cell Origin: Prognostic Significance of Histologic Subtypes. (2016) (49)
Poorly differentiated thyroid carcinoma presenting with gross extrathyroidal extension: 1986-2009 Memorial Sloan-Kettering Cancer Center experience. (2013) (48)
Ret/PTC activation in benign and malignant thyroid tumors arising in a population exposed to low-dose external-beam irradiation in childhood. (2004) (48)
Surgical management of the recurrent laryngeal nerve in thyroidectomy: American Head and Neck Society Consensus Statement (2018) (48)
A low postoperative nonstimulated serum thyroglobulin level does not exclude the presence of radioactive iodine avid metastatic foci in intermediate-risk differentiated thyroid cancer patients. (2013) (48)
Observation of clinically negative central compartment lymph nodes in papillary thyroid carcinoma. (2013) (48)
Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans. (2012) (48)
Microscopic Positive Margins in Differentiated Thyroid Cancer Is Not an Independent Predictor of Local Failure. (2015) (46)
Changing the Cancer Diagnosis: The Case of Follicular Variant of Papillary Thyroid Cancer-Primum Non Nocere and NIFTP. (2016) (44)
Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation. (2009) (44)
Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer (2015) (43)
Contemporary post surgical management of differentiated thyroid carcinoma. (2010) (41)
Multi‐institutional validation of a novel textural analysis tool for preoperative stratification of suspected thyroid tumors on diffusion‐weighted MRI (2015) (41)
Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer. (2005) (40)
Cost‐effectiveness analysis of papillary thyroid cancer surveillance (2015) (40)
Selective use of RAI for ablation and adjuvant therapy after total thyroidectomy for differentiated thyroid cancer: a practical approach to clinical decision making. (2013) (40)
Clinicopathologic Features of Fatal Non-Anaplastic Follicular Cell-Derived Thyroid Carcinomas. (2016) (39)
Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An 18F-FDG PET Study (2015) (39)
A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well-differentiated thyroid cancer. (2011) (39)
Treatment decision making in early‐stage papillary thyroid cancer (2018) (39)
Lateral Neck Lymph Node Characteristics Prognostic of Outcome in Patients with Clinically Evident N1b Papillary Thyroid Cancer (2015) (38)
Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer. (2018) (38)
Thyroid carcinoma. (2010) (36)
Multi-organ distant metastases confer worse disease-specific survival in differentiated thyroid cancer. (2014) (36)
Time Course and Predictors of Structural Disease Progression in Pulmonary Metastases Arising from Follicular Cell-Derived Thyroid Cancer. (2016) (36)
Thyroid Cancer Treatment Choice: A Pilot Study of a Tool to Facilitate Conversations with Patients with Papillary Microcarcinomas Considering Treatment Options. (2018) (34)
Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer. (2017) (34)
Using diffusion-weighted MRI to predict aggressive histological features in papillary thyroid carcinoma: a novel tool for pre-operative risk stratification in thyroid cancer. (2015) (33)
Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon. (2017) (33)
Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma? (2020) (33)
Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging. (2013) (32)
Erratum: American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer (Thyroid (2012) 22:11 (1104-1139)) (2012) (32)
Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features (2019) (32)
Frequent Screening With Serial Neck Ultrasound Is More Likely to Identify False-Positive Abnormalities Than Clinically Significant Disease in the Surveillance of Intermediate Risk Papillary Thyroid Cancer Patients Without Suspicious Findings on Follow-Up Ultrasound Evaluation (2015) (31)
Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases. (2014) (30)
Repeatability Investigation of Reduced Field-of-View Diffusion-Weighted Magnetic Resonance Imaging on Thyroid Glands (2015) (30)
Microarray Comparative Genomic Hybridization Reveals Genome-Wide Patterns of DNA Gains and Losses in Post-Chernobyl Thyroid Cancer (2006) (30)
ret/PTC activation is not associated with individual radiation dose estimates in a pilot study of neoplastic thyroid nodules arising in Russian children and adults exposed to Chernobyl fallout. (2008) (28)
No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial (2017) (28)
Micromedullary Thyroid Cancer: How Micro Is Truly Micro? (2009) (28)
Iatrogenic hyperthyroidism does not promote weight loss or prevent ageing‐related increases in body mass in thyroid cancer survivors (2012) (27)
Medullary carcinoma. (2010) (27)
Central lymph node characteristics predictive of outcome in patients with differentiated thyroid cancer. (2014) (26)
Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma. (2015) (25)
Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer. (2010) (25)
Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma. (2009) (25)
Comparable outcomes for patients with pT1a and pT1b differentiated thyroid cancer: Is there a need for change in the AJCC classification system? (2014) (24)
Clinical relevance of thyroglobulin doubling time in the management of patients with differentiated thyroid cancer. (2011) (24)
RAI thyroid bed uptake after total thyroidectomy: A novel SPECT‐CT anatomic classification system (2015) (24)
SERIAL NECK ULTRASOUND IS MORE LIKELY TO IDENTIFY FALSE-POSITIVE ABNORMALITIES THAN CLINICALLY SIGNIFICANT DISEASE IN LOW-RISK PAPILLARY THYROID CANCER PATIENTS. (2015) (24)
Database and registry research in thyroid cancer: striving for a new and improved national thyroid cancer database. (2015) (24)
GRADING OF MEDULLARY THYROID CARCINOMA ON THE BASIS OF TUMOR NECROSIS AND HIGH MITOTIC RATE IS AN INDEPENDENT PREDICTOR OF POOR OUTCOME (2020) (23)
Integration of a postoperative calcitonin measurement into an anatomical staging system improves initial risk stratification in medullary thyroid cancer (2015) (23)
Reply: Would Patient Selection Based on Both Calcitonin Blood Level and Doubling Time Improve 18F-FDG PET Sensitivity in Restaging of Medullary Thyroid Cancer? (2007) (23)
Current Management of Low Risk Differentiated Thyroid Cancer and Papillary Microcarcinoma. (2017) (23)
Active surveillance for patients with very low‐risk thyroid cancer (2020) (22)
A phase II study of single agent depsipeptide (DEP) in patients (pts) with radioactive iodine (RAI)-refractory, metastatic, thyroid carcinoma: Preliminary toxicity and efficacy experience. (2006) (21)
Treatment of thyroid cancer: 2007--a basic review. (2007) (21)
Natural history of small radioiodine-avid bone metastases that have no structural correlate on imaging studies (2014) (21)
Postoperative management of differentiated thyroid cancer. (2003) (21)
How many papillae in conventional papillary carcinoma? (2019) (20)
A Risk-adapted Approach to Follow-up in Differentiated Thyroid Cancer (2016) (20)
Screening for thyroid cancer in survivors of childhood and young adult cancer treated with neck radiation (2017) (20)
Primary high‐grade non‐anaplastic thyroid carcinoma: a retrospective study of 364 cases (2021) (20)
Preoperative neck ultrasound in clinical node-negative differentiated thyroid cancer. (2014) (19)
Radioactive iodine therapy in poorly differentiated thyroid cancer (2007) (19)
Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics. (2017) (19)
Disease-related death in patients who were considered free of macroscopic disease after initial treatment of well-differentiated thyroid carcinoma. (2011) (19)
Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease. (2018) (19)
Genomic and transcriptomic characterization of papillary microcarcinomas with lateral neck lymph node metastases. (2019) (19)
Investigational therapies for metastatic thyroid carcinoma. (2007) (19)
LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations (2015) (18)
What is the gold standard for comprehensive interinstitutional communication of perioperative information for thyroid cancer patients? A comparison of existing electronic health records with the current American Thyroid Association recommendations. (2014) (18)
Late‐Onset Medullary Carcinoma of the Thyroid: Need for Genetic Testing and Prophylactic Thyroidectomy in Adult Family Members (2006) (17)
Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. (2022) (17)
Complete blood counts are frequently abnormal 1 year after dosimetry-guided radioactive iodine therapy for metastatic thyroid cancer. (2014) (17)
Optimal management of a biochemical incomplete response to therapy in differentiated thyroid cancer: aggressive treatment or cautious observation? (2014) (16)
Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence. (2015) (16)
Improving the adoption of thyroid cancer clinical practice guidelines (2016) (16)
Thyroid Cancer Active Surveillance Program Retention and Adherence in Japan. (2020) (15)
Clinical Assessment and Risk Stratification in Differentiated Thyroid Cancer. (2019) (15)
Recombinant Human TSH-Assisted Radioactive Iodine Remnant Ablation in Thyroid Cancer Patients at Intermediate to High Risk of Recurrence. (2012) (15)
NATIONAL SURVEY OF ENDOCRINOLOGISTS AND SURGEONS REGARDING ACTIVE SURVEILLANCE FOR LOW-RISK PAPILLARY THYROID CANCER. (2021) (15)
Ethical Considerations When Counseling Patients With Thyroid Cancer About Surgery vs Observation. (2016) (14)
Prolongation of tumour volume doubling time (midDT) is associated with improvement in disease‐specific survival in patients with rapidly progressive radioactive iodine refractory differentiated thyroid cancer selected for molecular targeted therapy (2019) (14)
The Effect of Posttherapy 131 I SPECT / CT on Risk Classification and Management of Patients with Differentiated Thyroid Cancer (2010) (14)
Surgical Management of Low-/Intermediate-Risk Node Negative Thyroid Cancer: A Single-Institution Study Using Propensity Matching Analysis to Compare Thyroid Lobectomy and Total Thyroidectomy. (2021) (14)
Thyroid Carcinoma Clinical Practice Guidelines in Oncology (2010) (14)
Response to Therapy Status Is an Excellent Predictor of Pregnancy-Associated Structural Disease Progression in Patients Previously Treated for Differentiated Thyroid Cancer. (2017) (13)
Selective use of radioactive iodine in intermediate-risk papillary thyroid cancer. (2012) (13)
Papillary microcarcinoma of the thyroid (2007) (13)
Disease-related and treatment-related unfavorable events in the management of low-risk papillary microcarcinoma of the thyroid by active surveillance versus immediate surgery (2017) (13)
Observing micopapillary thyroid cancers. (2014) (13)
Improving the quality of thyroid cancer care: how does the Thyroid Cancer Care Collaborative cross the Institute of Medicine's Quality Chasm? (2014) (13)
Recombinant human thyroid-stimulating hormone to stimulate 131-I uptake for remnant ablation and adjuvant therapy. (2013) (12)
Management and outcome of clinically evident neck recurrence in patients with papillary thyroid cancer (2017) (12)
Structural doubling time predicts overall survival in patients with medullary thyroid cancer in patients with rapidly progressive metastatic medullary thyroid cancer treated with molecular targeted therapies. (2020) (12)
Prevalence of diabetes mellitus in patients with newly evaluated papillary thyroid cancer (2014) (12)
Management of Retropharyngeal Lymph Node Metastases in Differentiated Thyroid Carcinoma. (2020) (12)
Medullary Thyroid Carcinoma: Ethical Issues for the Surgeon (2012) (12)
What have we learnt from Chernobyl? What have we still to learn? (2011) (12)
Challenges of Active Surveillance Protocols for Low-Risk Papillary Thyroid Microcarcinoma in the United States. (2016) (12)
American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence‐based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules (2019) (12)
Appropriate Use Criteria for Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer (2020) (12)
Implementing Key Changes in the American Thyroid Association 2015 Thyroid Nodules/Differentiated Thyroid Cancer Guidelines Across Practice Types. (2018) (11)
Effectiveness of routine ultrasonographic surveillance of patients with low-risk papillary carcinoma of the thyroid. (2016) (11)
Dynamic contrast‐enhanced MRI model selection for predicting tumor aggressiveness in papillary thyroid cancers (2020) (11)
Surgical considerations for papillary thyroid microcarcinomas (2017) (11)
Editorial: Risk of disease progression during active surveillance of papillary thyroid cancer. (2017) (11)
Prophylactic Lateral Neck Dissection for Medullary Thyroid Carcinoma is not Associated with Improved Survival (2021) (11)
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA) (2022) (10)
Effect of 5‐α‐reductase inhibition and dexamethasone administration on the growth characteristics and intratumor androgen levels of the human prostate cancer cell line PC‐3 (1994) (10)
Invasion of a Recurrent Laryngeal Nerve from Small, Well-Differentiated Papillary Thyroid Cancers: Patient Selection Implications for Active Surveillance. (2021) (10)
Follicular and Hurthle Cell Carcinoma: Comparison of Clinicopathological Features and Clinical Outcomes. (2022) (10)
American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment (2022) (10)
Is a Prophylactic Central Compartment Neck Dissection Required in Papillary Thyroid Carcinoma Patients with Clinically Involved Lateral Compartment Lymph Nodes? (2020) (10)
Can risk-adapted treatment recommendations replace the 'one size fits all' approach for early-stage thyroid cancer patients? (2009) (9)
Role of RAI in the management of incidental N1a disease in papillary thyroid cancer (2016) (9)
Data set for reporting carcinoma of the thyroid: Recommendations from the International Collaboration on Cancer Reporting (ICCR). (2020) (9)
A phase II study of VEGF trap (aflibercept) in patients with radioactive iodine-refractory, positron emission tomography (PET) positive thyroid carcinoma. (2010) (9)
Similarities and differences in follicular cell-derived thyroid cancer management guidelines used in Europe and the United States. (2011) (9)
Non-surgical thermal ablation of thyroid nodules. Not if, but why, when, and how? (2020) (8)
Restricting ultrasound thyroid fine needle aspiration biopsy by nodule size: which tumors are we missing? A population-based study (2016) (8)
Thyroid cancer staging and genomics. (2019) (8)
Risk Classification and Management of Patients with Differentiated Thyroid Cancer (2010) (8)
Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer (2016) (7)
Reacquisition of RAI uptake in RAI-refractory metastatic thyroid cancers by pretreatment with the MEK inhibitor selumetinib. (2012) (7)
PRACTICAL BARRIERS TO IMPLEMENTATION OF THYROID CANCER GUIDELINES IN THE ASIA-PACIFIC REGION. (2015) (7)
Patients with high‐risk differentiated thyroid cancer have a lower I‐131 ablation success rate than low‐risk ones in spite of a high ablation activity (2016) (7)
Patients with Multifocal Macroscopic Papillary Thyroid Carcinoma Have a Low Risk of Recurrence at Early Follow-Up after Total Thyroidectomy and Radioactive Iodine Treatment (2016) (7)
Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer (2012) (7)
Metabolic parameters that predict response to clomiphene citrate in obese oligo-ovulatory women. (1996) (6)
Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low‐risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary (2017) (6)
Inappropriate Use of Radioactive Iodine for Low-Risk Papillary Thyroid Cancer Is Most Common in Regions with Poor Access to Healthcare. (2015) (6)
Undetectable Thyroglobulin Levels in Poorly Differentiated Thyroid Carcinoma Patients Free of Macroscopic Disease After Initial Treatment: Are They Useful? (2015) (6)
Assessing the Number of Candidates There Are for Active Surveillance of Low-Risk Papillary Thyroid Cancers in the US. (2020) (6)
Quantitative Non-Gaussian Intravoxel Incoherent Motion Diffusion-Weighted Imaging Metrics and Surgical Pathology for Stratifying Tumor Aggressiveness in Papillary Thyroid Carcinomas (2019) (5)
Summary of proceedings of the second World Congress on Thyroid Cancer (2014) (5)
Multifocality in papillary thyroid carcinoma-An unresolved controversy. (2020) (5)
No calcitonin change in a person taking dulaglutide diagnosed with pre‐existing medullary thyroid cancer (2018) (5)
Long-Term Oncologic Outcomes After Curative Resection of Familial Medullary Thyroid Carcinoma (2019) (5)
Patient Perspectives on the Extent of Surgery and Radioactive Iodine Treatment for Low-Risk Differentiated Thyroid Cancer. (2021) (5)
Enhancing radioiodine (RAI) incorporation into BRAFV600E-mutant, RAI-refractory thyroid cancers with the BRAF inhibitor vemurafenib: A pilot study. (2016) (5)
Thyroid Nodule and Differentiated Thyroid Cancer Guidelines (2010) (5)
How Does The AJCC/TNM Staging System Eighth Edition Perform in Thyroid Cancer at A Major Middle Eastern Medical Center? (2020) (4)
ATA HIGH-RISK THYROID CANCER PATIENTS DEMONSTRATING AN EXCELLENT RESPONSE TO THERAPY WITHIN A FEW WEEKS OF INITIAL THERAPY HAVE BETTER THAN EXPECTED CLINICAL OUTCOMES. (2019) (4)
Distinguishing remnant ablation from adjuvant treatment in differentiated thyroid cancer. (2019) (4)
Brief progress report from the intersocietal working group on differentiated thyroid cancer (2020) (4)
Intensity‐modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial (2021) (4)
The Delphian Node Revisited: An Uncommon Site of Recurrence (2017) (4)
A phase II study of VEGF trap in patients with radioactive iodine (RAI)-refractory thyroid carcinoma. (2011) (4)
Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer (2019) (4)
Papillary thyroid microcarcinoma and active surveillance - Authors' reply. (2016) (3)
Radiation therapy and low dose doxorubicin in thyroid cancer: A phase II study. (2016) (3)
mutation and glucose metabolism in thyroid cancer patients : An 18 F-FDG-PET study (2015) (3)
Radioiodine Dosimetry with Recombinant Human Thyrotropin (2006) (3)
Ultrasonographic characterization of cervical lymphadenopathy in chronic autoimmune thyroiditis. (2013) (3)
Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry (2020) (3)
Perioperative diagnostics of patients referred for radioiodine therapy of differentiated thyroid carcinoma: referral center experience in an iodine-insufficient country (2020) (3)
Best Use of the Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer: Discussion. (2016) (3)
Radioiodine (RAI) in combination with durvalumab for recurrent/metastatic thyroid cancers. (2020) (3)
The 2009 American Thyroid Association guidelines modestly reduced radioactive iodine use for thyroid cancers less than 1 cm. (2014) (3)
The solid variant of papillary thyroid carcinoma: a multi‐institutional retrospective study (2022) (3)
THE ROLE OF ELECTRONIC FEEDBACK LOOPS IN THE CONTINUOUS QUALITY IMPROVEMENT OF THYROID NODULE AND THYROID CANCER CARE. (2017) (2)
Frequent neck US in papillary thyroid cancer likely detects non‐actionable findings (2020) (2)
Surgical Management of Low-/Intermediate-Risk Node Negative Thyroid Cancer: A Single-Institution Study Using Propensity Matching Analysis to Compare Thyroid Lobectomy and Total Thyroidectomy (2022) (2)
Impact of Surgery and External Beam Radiation Therapy on Local Control in the Treatment of Medullary Thyroid Carcinoma (2018) (2)
Even without additional therapy, serum thyroglobulin levels often decline for years after total thyroidectomy and RAI remnant ablation. (2012) (2)
Ultrasound-Guided Percutaneous Laser Ablation of the Thyroid Gland in a Swine Model: Comparison of Ablation Parameters and Ablation Zone Dimensions. (2021) (2)
Tumor Grade Predicts for Calcitonin Doubling Times and Disease-Specific Outcomes After Resection of Medullary Thyroid Carcinoma. (2022) (2)
An Overview of the Management of Thyroid Cancer (2010) (2)
Active surveillance of papillary thyroid cancer-frequency and time course of the 6 most common tumor volume kinetic patterns. (2022) (2)
Clinicopathologic and Prognostic Features of Pediatric Follicular Cell–derived Thyroid Carcinomas (2022) (1)
ThyroidEx: Development and Preliminary Validation of a Thyroid Surgery Expectations Measure (2020) (1)
Medullary Carcinoma Clinical Practice Guidelines in Oncology TM (2010) (1)
Augmenting pre-operative risk of recurrence stratification in differentiated thyroid carcinoma using machine learning and high dimensional transcriptional data from thyroid FNA. (2015) (1)
Frozen section of central lymph nodes in thyroid cancer. (2022) (1)
What's in a Name? A Cost-Effectiveness Analysis of the Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) Nomenclature Revision. (2021) (1)
Initial Treatment of Progressive Differentiated Thyroid Cancer. (2016) (1)
Enhanced interdisciplinary communication: development of an interactive thyroid nodule/cancer disease map (2018) (1)
Treatment of Metastatic Thyroid Cancer with Radioiodine Following Preparation by Recombinant Human Thyrotropin (2016) (1)
Risk Stratification and Current Management of Low Risk Thyroid Cancer (2018) (1)
Level 7 Disease Does Not Confer Worse Outcome than Level 6 Disease in Differentiated Thyroid Cancer (2015) (1)
The “broken chair” in patients with differentiated thyroid cancer (2017) (1)
Does macroscopic extrathyroidal extension to the strap muscles alone affect survival in papillary thyroid carcinoma? (2021) (1)
Nuances in the Surgical Management of Thyroid Cancer (2021) (1)
A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image Guided Stereotactic Body Radiotherapy (SBRT) in the Treatment of Metastatic Anaplastic Thyroid Cancer. (2022) (1)
Previous External Beam Radiation Treatment Exposure Does Not Confer Worse Outcome for Patients with Differentiated Thyroid Cancer. (2017) (1)
Pediatric Thyroid Cancer: A Surgical Challenge. (2019) (1)
Reply: Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details (2017) (1)
Surgical management of T1/T2 node-negative papillary thyroid cancer with tall cell histology: Is lobectomy enough? (2022) (1)
Response to Letter: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine? (2017) (0)
Delphian node—A sentinel node in thyroid cancer? (2021) (0)
Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy (2022) (0)
55. Clearance of radioiodine in thyroid cancer patients: a comparison of thyroid hormone withdrawal with recombinant human TSH administration (2001) (0)
Role of diffusion weighted magnetic resonance imaging in stratifying tumor aggressiveness in papillary thyroid carcinoma (2012) (0)
Nomogram Using Host and Tumor Factors to Predict Survival in Individual Patients with Well Differentiated Thyroid Cancer (2022) (0)
Thyroid Cancer Guidelines Task Force Disclosure Information (2009) (0)
Reply: Active Surveillance in Micropapillary Carcinoma. (2018) (0)
Effect of Beta-Adrenergic Blockade and Definitive Therapy on Cognitive Dysfunction in Thyrotoxicosis. (1996) (0)
Abnormal growth rate of a benign cervical sympathetic chain schwannoma (2021) (0)
Papillary microcarcinoma—Management issues (2021) (0)
Letter to the Editor from Boucai, L and Tuttle, RM: "BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer". (2022) (0)
Management of Thyroid Cancer (2009) (0)
Phase 2 Trial of Intensity-Modulated Radiation Therapy +/- Concurrent Doxorubicin for Patients With Locally Advanced or Recurrent Non-anaplastic Thyroid Cancer (2017) (0)
Dynamic Risk Group Analysis and Staging for Differentiated Thyroid Cancer (2021) (0)
Cancer Metastasis: Metastatic Thyroid Cancer: Evaluation and Treatment (2011) (0)
Psychological adjustment to initial treatment for low‐risk thyroid cancer: Preliminary study (2022) (0)
Hemithyroidectomy for Differentiated Thyroid Cancer (2021) (0)
131I Treatment of Metastatic Thyroid Carcinoma Following Preparation by Recombinant Human Thyrotropin (2006) (0)
Thyroid Cancer (2020) (0)
AssociationBetween BRAFV600EMutationand MortalityinPatientsWithPapillaryThyroidCancer (2013) (0)
Risk Stratification in Differentiated Thyroid Cancer: Importance and Clinical Implications of Preoperative Risk Stratification (2018) (0)
Papillary Carcinoma Observation (2021) (0)
External Beam Radiation With or Without Concurrent Chemotherapy in Non-anaplastic Thyroid Cancer With Unresectable or Gross Residual Disease (2017) (0)
Role of External Radiation Therapy in Patients With Advanced or Recurrent Non-Anaplastic Thyroid Cancer: The Memorial Sloan-Kettering Cancer Center Experience (2007) (0)
Postoperative Surveillance for Recurrent Malignant Disease (2012) (0)
Clinical Outcomes of Differentiated Thyroid Cancer With Gross Extrathyroidal Extension Into the Strap Muscles: A Case Control Study (2021) (0)
Short Communication Genome-Wide Appraisal of Thyroid Cancer Progression (2002) (0)
Response to: Letter to the Editor Regarding the Article "Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma". (2015) (0)
Optimal Treatment for Papillary Microcarcinoma (2016) (0)
Ernest L. Mazzaferri, MD, MACP (1936-2013). (2013) (0)
Management of the contralateral central neck in differentiated thyroid cancer: A contentious issue. (2021) (0)
Papillary Thyroid Microcarcinoma: Surveillance or Immediate Biopsy, Surgery? (2016) (0)
Reply: A New Age for Recombinant Human Thyroid-Stimulating Hormone? (2009) (0)
Percutaneous ablation of low-risk papillary thyroid cancer. (2023) (0)
Welcome to the 84th annual meeting of the American Thyroid Association. (2014) (0)
Lymphovascular invasion and active surveillance in thyroid cancer. (2020) (0)
AssociationBetween BRAF V 600 EMutationand MortalityinPatientsWithPapillaryThyroidCancer (2013) (0)
Comparison of empiric fixed dosing with a whole body/blood clearance dosimetry based management approach to radioactive iodine treatment in patients with RAI avid distant metastases from differentiated thyroid cancer. (2015) (0)
Thyroid Remnant Radioiodine Ablation with Recombinant Human Thyrotropin (2006) (0)
Predicting bone marrow toxicity from treatment with I-131 Sodium Iodide (NaI) (2015) (0)
Practice patterns in the management of thyroid cancer (2022) (0)
Commentary: Re-recurrence after surgical management of recurrent thyroid cancer. (2020) (0)
MON-520 How Does the American Joint Committee on Cancer 8thEdition Tumor, Node, Metastasis Staging System Perform in Patients Evaluated at a Major Middle Eastern Medical Center? (2020) (0)
Postoperative Management of Well-Differentiated Thyroid Cancer (2009) (0)
Tumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer. (2018) (0)
2013 Meet-The-Professor: Endocrine Case Management (2013) (0)
Commentary "Incidence of total thyroidectomy and lobectomy". (2019) (0)
Chapter 6 The role of fluoro-deoxy glucose (FDG) positron emission tomography (PET) in the management of differentiated thyroid cancer (2006) (0)
Large (>4 cm) Intrathyroidal Encapsulated Well-Differentiated Follicular Cell-Derived Carcinoma Without Vascular Invasion May Have Negligible Risk of Recurrence Even When Treated with Lobectomy Alone. (2023) (0)
1715 Assessment of tumor aggressiveness using intravoxel incoherent motion MRI in patients with papillary thyroid carcinoma (2013) (0)
Treatment of Advanced Thyroid Cancer (2015) (0)
In Reply to Drs. Mehrotra and Mishra (2010) (0)
Dynamic Risk Stratification for Recurrence in Medullary Thyroid Cancer (2013) (0)
Abstract 4012: Drug-Eluting Stent Use Is Associated with Significant Improvements in Long-Term Clinical Outcomes (2006) (0)
Radioactive iodine therapy: multiple faces of the same polyhedron (2022) (0)
Emerging Trends in Differentiated Thyroid Cancer Management (2006) (0)
Thyroid carcinoma. (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Robert Michael Tuttle?

Robert Michael Tuttle is affiliated with the following schools:

University of Ulsan College of Medicine